SAN DIEGO & BERLIN–(BUSINESS WIRE)–Vividion announces first patient dosed in Phase 2 clinical trial of VVD-214, an investigational oral inhibitor of Werner helicase (WRN).

Subscribe to Our Newsletter

We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.